Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | CYP1A1 | P04798 | 11/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 11/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | JUN | P05412 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.67 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196640 | 1.00 | PFKFB3 (1.00) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL29458617 | 1.00 | PFKFB3 (1.00) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL13479662 | 0.93 | RAB9A (0.88) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL979409 | 0.90 | CYP1B1 (0.83) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL7368933 | 0.90 | CYP1B1 (0.83) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL1604140 | 0.87 | RAB9A (1.00) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL5646960 | 0.87 | RAB9A (1.00) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL29600034 | 0.87 | RAB9A (1.00) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL6700090 | 0.86 | RAB9A (0.76) | PFKFB3RAB9AMAPTKMT2ACYP1A1 | |
| SCHEMBL6794938 | 0.86 | RAB9A (0.76) | PFKFB3RAB9AMAPTKMT2ACYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | claimed |
| US-20250242030-A1 | COMPOSITIONS COMPRISING A NON-BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-07-31 | — | — | US | claimed |
| US-20250135072-A1 | COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-05-01 | — | — | US | claimed |
| EP-4510829-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | The Regents of University of California (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | claimed |
| US-20230312728-A1 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | claimed |
| CN-116615241-A | Methods and compositions for diabetes treatment and beta cell regeneration | 加利福尼亚大学董事会 | 2023-08-18 | — | — | CN | claimed |
| WO-2023147055-A1 | COMPOSITIONS COMPRISING A NON-BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023147048-A1 | COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-08-03 | — | — | WO | claimed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| CN-112970914-B | Chocolate cream inhibiting agent and preparation method thereof | 江南大学 | 2022-07-19 | — | — | CN | claimed |
| WO-2022112439-A1 | DIAGNOSTIC METHODS FOR INFLAMMATORY DISEASE | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2022-06-02 | — | — | WO | claimed |
| WO-2022040161-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-24 | — | — | WO | claimed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2008156783-A2 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156783-A2 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | PFKFB3 2759/4885RAB9A 2782/4885MAPT 1033/4885 |
| US-12630638-B2 | Methods and compositions for diabetes treatment and β-cell regeneration | IAPP, APP, SLC2A3 | PFKFB3 27/4885RAB9A 4624/4885MAPT 370/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | PFKFB3 485/4885RAB9A 3197/4885MAPT 1652/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PFKFB3 4527/4885RAB9A 2655/4885MAPT 3816/4885 |
| US-20090074884-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | PFKFB3 1/4885RAB9A 3717/4885MAPT 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.